Skip to main
CNTX

CNTX Stock Forecast & Price Target

CNTX Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Context Therapeutics is expected to see major success in the biopharmaceutical industry due to its promising preclinical program and pipeline of therapies focused on treating hormone-dependent cancers. The company's clinical execution story, with two Phase 1a bispecific readouts expected in 2026, along with a third program moving towards the clinic, creates a strong momentum for Context Therapeutics. The company's strong financial position, with $76.9M in cash and cash equivalents as of September 30, 2025, provides a sufficient runway for operations until mid-2027, allowing investors to focus on data from upcoming clinical trials. The company's innovative approach utilizing bispecific antibody technology and pH-dependent binding is expected to result in quick proof-of-concept for its programs, potentially attracting potential partners and driving investor interest.

Bears say

Context Therapeutics is a biopharmaceutical company with a negative outlook due to potential risks in clinical trials, financial concerns, and competition in the market. Despite a promising pipeline targeting hormone-dependent cancers, the company's early stage development and recent update on its Phase 1a trial for CTIM-76 raise concerns about its ability to achieve proof-of-concept and attract potential partners or investors. Additionally, the update on CT-95's dosing and target exposure suggest potential delays in reaching milestones.

CNTX has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Context Therapeutics LLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Context Therapeutics LLC (CNTX) Forecast

Analysts have given CNTX a Strong Buy based on their latest research and market trends.

According to 5 analysts, CNTX has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Context Therapeutics LLC (CNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.